Drug Trial Radar · NCT07732023
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Jul 30, 2028
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase Ib study to evaluate the safety, tolerability, efficacy, PK/PD characteristics, and immunogenicity of SKB575 (HBM7575) injection in subjects with asthma.
Conditions
- Asthma (Diagnosis)
Interventions
SKB575Drug
Subcutaneous
PlaceboDrug
Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of participants with adverse events (AEs), serious adverse events (SAE)Time frame: From baseline to week 32
- Changes of fractional exhaled nitric oxide (FeNO) compared with baseline at week 8Time frame: Week 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.